Should we be using psychedelics or dissociatives to treat mental health conditions?
Cassidy O'Brien, Sabrina Fields
Zenodo (CERN European Organization for Nuclear Research) March 12, 2026 preprint DOI: 10.5281/zenodo.18988759 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Key findings | The paper sets out to analyze the clinical and ethical debate over using psychedelics or dissociatives as primary treatments for mental health conditions; the text provided does not state its conclusions or arguments. |
Abstract
This white paper was developed for BIOL 700, a seminar-style course at the University of New Hampshire that explores the intersection of biological science, ethics, and public policy. The report provides a comprehensive analysis of the clinical and ethical debate surrounding the question: "Should psychedelics or dissociatives be utilized as primary treatments for mental health conditions?"